Skip to content

Stealth Protocell System Based on Folated Polyoxyethylene Stearyl Ether-Modified Liposome-Encapsulated Mesoporous Silica for Active Tumor Targeting and pH-Responsive Releasing

Sep 2026 · ACS Applied Engineering Materials · Vol 4, pp. 5394-5406 · 0 citations · 47 references

TL;DR

The development of a hybrid nanocarrier consisting of an MSN core encapsulated within a lipid bilayer modified with folated polyoxyethylene stearyl ether to highlight the potential of the MLBF as a sophisticated platform for targeted and stimuli-responsive cancer treatment.

Abstract

Controlled drug release and enhanced cellular accumulation are critical strategies for improving the efficacy of mesoporous silica nanoparticle (MSN) carriers in cancer therapy. This study describes the development of a hybrid nanocarrier (MLBF) consisting of an MSN core encapsulated within a lipid bilayer modified with folated polyoxyethylene stearyl ether (Brij-FA). This stealth protocell design utilizes Brij-FA to provide a protective steric layer aimed at reducing non-specific clearance while promoting cellular uptake. Physicochemical characterization using Fourier transform infrared, energy-dispersive X-ray spectroscopy, and thermogravimetric analysis confirmed the successful assembly of the LBF shell onto the aminated MSN. The resulting spherical nanoparticles exhibited a hydrodynamic diameter of 191.8 ± 3.2 nm and a zeta potential of −24.4 mV. Using doxorubicin (DOX) as a model cargo, the MLBF system demonstrated distinct pH-responsive release behavior, with significantly higher release rates in simulated tumor microenvironments (pH 5.5) compared to physiological conditions (pH 7.4). In vitro assessments on HeLa cells revealed excellent biocompatibility for the carrier, while DOX-loaded MLBF exhibited potent cytotoxicity comparable to that of the free drug. Confocal microscopy verified superior intracellular internalization of the MLBF system compared to non-folated counterparts, which is likely driven by a combination of favorable physicochemical properties and potential interactions with folate receptors. These findings highlight the potential of the MLBF as a sophisticated platform for targeted and stimuli-responsive cancer treatment.

View source

Similar papers

Sep 2026

Co-loaded pH-Responsive AOT Nanovesicles for Combinatorial Chemotherapy: Structure, Stability, and Mechanism of Drug Release and Anti-Cancer Activity.

The development of biocompatible sodium bis(2-ethylhexyl) sulfosuccinate (AOT)-based nanovesicles for the co-delivery of hydrophilic and hydrophobic anti-cancer agents, doxorubicin and curcumin are reported.

Khushnuma Asghar, Kumari Kiran, Bharath Raj Parthasarathy et al. · 0 citations
Sep 2026

Exploiting Binary Eutectic Fatty Acid Systems for Thermoresponsive Nanocarriers: A Doxorubicin Delivery Approach

The developed stearic acid/lauric acid binary eutectic thermoresponsive lipid nanoparticles exhibited favorable physicochemical properties, thermoresponsive drug release, biocompatibility, and enhanced anticancer activity, highlighting their potential for thermoresponsive doxorubicin delivery in cancer therapy.

Maryam Anwar, Mubashar Rehman, Asim ur. Rehman et al. · 0 citations
Aug 2026

Curcumin-loaded PEGylated Magnetic Iron Oxide Nanoparticles: a Biogenic Platform for Targeted and Controlled Drug Release.

The synergistic combination of green synthesis, magnetic targeting capability, pH-triggered drug release, and superior anticancer efficacy highlights Fe3O4@PEG-CUR-NPs as a promising nanotherapeutic platform for precision cancer treatment and advanced biomedical applications.

K. Vijayalakshmi, A. Kavitha, S. Ayyanaar · 0 citations
Sep 2026

Multifunctional Cyclodextrin–PEG–folate-coated Ytterbium Ferrite– hydroxyapatite Nanoparticles for pH-sensitive Anticancer Drug Delivery

This work is centered on the formulation of a magnetic, targeted drug delivery system using cyclodextrin–polyethylene glycol–folate (CD-PEG-fol) polymer-coated hydroxyapatite (HAp) nanoparticles with incorporated ytterbium ferrite/ytterbium iron nanoparticles for targeted camptothecin delivery. Yb-Fer-HAp na...

Kiruthiga Kaliyamoorthi, U. Tamboli, Sudhaker Raboni Grace et al. · 0 citations
Sep 2026

Tailoring biodegradable polycaprolactone-polyethylene glycol coating on mesoporous silica nanoparticles: optimization of chain length for enhanced enzyme-triggered drug release in cancer therapy.

Poly(ε-caprolactone) (PCL) is a biodegradable polymer extensively explored for drug delivery applications, particularly in cancer therapy. However, tailoring its degradation kinetics is critical for designing efficient stimuli-responsive nanocarriers. In this study, we systematically optimized the chain length of PCL t...

Tien-Dung Nguyen-Dinh, Minh-Triet Nguyen-Vo, Cuong Hung Luu et al. · 0 citations
Sep 2026

Exploiting the rubbery-state transition of PLGC nanoparticles for enhanced intracellular paclitaxel delivery and anti-tumor efficacy.

The therapeutic efficacy of polymeric nanocarriers is often restricted by rigid, glassy matrices that hinder drug diffusion and poorly controlled surface interactions that limit cellular uptake. This study exploits the temperature-induced, rubbery-state transition of poly(lactide-co-glycolide-co-caprolactone) (PLGC) na...

Nuttawut Khammata, Wanwanut Chueasupcharoen, Chawan Manaspon et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.